Anagenesis Biotechnologies

What Anagenesis Biotechnologies does

Anagenesis Biotechnologies is a private, for-profit biotechnology company headquartered in Illkirch-Graffenstaden, France, founded in 2001. The company is focused on developing novel treatments for genetic and age-related muscle degenerative diseases, positioning it within the rare/genetic disease and age-related therapeutics segment of the biotech industry.

The company operates as a small research-stage organization with 1-10 employees, suggesting a lean, likely pre-clinical or early clinical development stage posture. It is founder-led, with Jean-Yves Bonnefoy serving as co-founder, president, and CEO, providing centralized scientific and strategic direction. The public footprint is minimal — a basic corporate website (anagenesis-biotech.com) — with no disclosed product pipeline details, no named customers or partners, no disclosed funding rounds, and no revenue data in the available source material.

The business model and revenue mechanics cannot be characterized from the available evidence. No pricing, go-to-market, licensing, or partnership monetization signals are present, and the bulk of the source material relates to unrelated third-party content (a gambling site and an electronics wholesale marketplace) that does not pertain to the company. As such, the description above is necessarily limited to what the firmographic and short_description inputs directly support.

Name

Anagenesis Biotechnologies

Website

https://anagenesis-biotech.com

Company type

Private

Founded year

2001

Headcount range

1–10 employees

Short description

Anagenesis Biotechnologies is a France-based, private biotechnology company founded in 2001 that develops novel treatments for genetic and age-related muscle degenerative diseases, operating as a small founder-led research-stage organization.

Ownership category

akta.pro rank

Product category

Muscular Dystrophy Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industries

Therapeutic Enzymes & Enzyme Replacement Therapies (ERT) (HLAAAAAK), Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)

Keywords

• Muscular dystrophy treatments
• Muscle regenerative therapies
• Biopharmaceutical research
• Genetic disease therapeutics
• Age-related muscle therapy

Headquarters

HQ city

Illkirch-graffenstaden

HQ country

France

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Anagenesis Biotechnologies focuses on developing novel therapeutic treatments for genetic and age-related muscle degenerative diseases. The company conducts biopharmaceutical research aimed at muscle regeneration and repair, with the goal of creating new therapeutic options for conditions such as muscular dystrophies and related degenerative muscle disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Novel muscle degenerative disease therapeutics

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Pfizer: Global biopharma with rare disease and muscle-related programs and recent acquisitions in gene therapy. Comparable as a large incumbent with active interest in neuromuscular therapeutics.
• Sanofi: European-headquartered biopharma with rare disease and muscle programs (e.g., Pompe, SMA franchises). Comparable as a broad incumbent in genetic muscle disorders with a European footprint relevant to Anagenesis' base.
• Novartis (Gene Therapy unit): Commercialized Zolgensma for spinal muscular atrophy and continues to invest in neuromuscular gene therapy. Comparable as a major player in genetic muscle/neuromuscular disorders.
• BioMarin Pharmaceutical: Established rare-disease biopharmaceutical company with approved enzyme replacement and gene therapies. Comparable as a broader incumbent in genetic/rare neuromuscular and metabolic disorders.
• Regeneron Pharmaceuticals: Large biotech developing antibody and biologic therapies including muscle and rare-disease programs. Comparable as a biologics platform with muscle-relevant therapeutic activity.

Emerging players

• Capricor Therapeutics: Develops cell-derived exosome and cell therapy candidates for Duchenne muscular dystrophy and cardiac indications. Comparable as a biologics-based developer in the muscle-degenerative disease space.
• Catabasis Pharmaceuticals: Was a clinical-stage developer of novel small molecules for Duchenne muscular dystrophy and other rare diseases. Comparable as a niche muscle-disease biotech (note: company has undergone restructuring, included as historical peer).
• Solid Biosciences: Clinical-stage gene therapy company focused on Duchenne muscular dystrophy and other neuromuscular disorders. Comparable as a niche muscle-disease biotech pursuing novel biologics/gene-based modalities.

Direct peers

• Sarepta Therapeutics: Commercial-stage leader in Duchenne muscular dystrophy and other genetic muscle diseases, with approved exon-skipping and gene therapies. Directly comparable because Anagenesis also targets genetic and degenerative muscle indications.
• PTC Therapeutics: Develops small-molecule and splicing therapies for Duchenne muscular dystrophy and other rare genetic disorders. Comparable therapeutic focus on inherited muscle degenerative diseases.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/anagenesis-biotechnologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anagenesis Biotechnologies